SGCB

Beta-sarcoglycan (SGCB) is a striated-muscle transmembrane protein that assembles with α-, γ-, and δ-sarcoglycan into a four-subunit sarcoglycan complex at the sarcolemma, and its loss destabilizes the entire complex and reduces alpha-dystroglycan at the membrane (PMID:9565988, PMID:37317968). Although SGCB is transcribed broadly during early human development, expression becomes restricted to striated muscle, heart, and central nervous system, with sarcoglycan protein accumulation concentrated in muscle (PMID:9521867). Pathogenic SGCB mutations eliminate all sarcoglycans from the sarcolemma and cause limb-girdle muscular dystrophy type 2E with dilated cardiomyopathy, establishing a requirement for SGCB in both skeletal and cardiac muscle (PMID:9565988, PMID:12868499). AAV-mediated restoration of human SGCB in Sgcb-null mice re-assembles the sarcoglycan complex, protects the sarcolemma from membrane permeability, reduces fibrosis, and restores muscle force, directly linking SGCB to membrane integrity and contractile function (PMID:26214262, PMID:28284983). Deep mutational scanning across all possible SGCB amino acid changes shows that variants intolerant to substitution cluster at predicted inter-subunit interaction interfaces, defining the residues that mediate complex assembly and cell-surface localization (PMID:37317968).

1. 1998 Medium

   Established that SGCB is not merely one of several sarcoglycans but is required for stability of the whole complex, and that the complex in turn anchors alpha-dystroglycan at the membrane.

   Evidence Immunohistochemistry and immunoblot of LGMD2E patient muscle biopsies carrying SGCB point mutations

   PMID:9565988

   Open questions at the time

   • Loss-of-function inference from patient material does not resolve the order of complex assembly
   • Does not define which residues mediate inter-subunit contacts
2. 1998 Medium

   Resolved the developmental and tissue expression pattern of SGCB, showing a shift from ubiquitous transcription to striated-muscle-restricted protein accumulation.

   Evidence In situ hybridization and immunodetection on staged human embryonic/fetal tissue sections

   PMID:9521867

   Open questions at the time

   • Mechanism restricting protein accumulation to muscle despite broad transcription is unexplained
   • CNS functional role not addressed
3. 2003 Medium

   Demonstrated that SGCB function extends beyond skeletal muscle, as loss causes dilated cardiomyopathy alongside sarcoglycan loss in muscle.

   Evidence Immunoblot/immunohistochemistry on biopsies plus echocardiography in six LGMD2E patients

   PMID:12868499

   Open questions at the time

   • Small single-center cohort
   • Does not establish cardiac-autonomous mechanism distinct from skeletal disease
4. 2015 High

   Provided causal evidence that restoring SGCB alone re-builds the complex and rescues membrane integrity and force, confirming SGCB as the limiting subunit in LGMD2E muscle.

   Evidence Isolated-limb AAV delivery of codon-optimized hSGCB in Sgcb-null mice with membrane permeability, force, and histology readouts

   PMID:26214262

   Open questions at the time

   • Localized delivery does not address systemic or cardiac correction
   • Durability of rescue not defined
5. 2017 High

   Extended SGCB restoration to a systemic, whole-body context, showing rescue of respiratory muscle function and ambulation, supporting therapeutic feasibility.

   Evidence Systemic tail-vein AAV delivery in SGCB-knockout mice with serum CK, diaphragm force, locomotion, and spine imaging

   PMID:28284983

   Open questions at the time

   • Long-term immune and safety profile in disease-relevant species not addressed
   • Cardiac functional rescue not quantified
6. 2023 High

   Mapped the functional sequence determinants of SGCB at single-residue resolution, defining the inter-subunit interfaces required for complex assembly and surface localization and enabling variant pathogenicity prediction.

   Evidence Deep mutational scanning of all 6,340 amino acid changes with sarcoglycan complex cell-surface localization readout and structural modeling

   PMID:37317968

   Open questions at the time

   • Cell-surface assay may not capture all in vivo functions
   • Structural models validated functionally but not by experimental atomic structure

• The biochemical role of SGCB in the CNS and the mechanism coupling the sarcoglycan complex to downstream signaling or alpha-dystroglycan stabilization remain undefined.
• No direct enzymatic or signaling activity assigned to SGCB
• CNS function not characterized in the available corpus